Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.